DSLT for Reducing Medication in Glaucoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Voyager DSLT.
- Who it may be relevant to
- Registry conditions: Primary Open Angle Glaucoma, Ocular Hypertension. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma
Overview
This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT. Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.
Interventions
- Device Voyager DSLT
Voyager DSLT
Primary outcome measures
- Reduction in the number of glaucoma medications required to maintain target intraocular pressure (IOP) [Time frame: 6 months post-DSLT treatment]
Secondary outcome measures (3)
- Change in intraocular pressure (IOP) from baseline [Time frame: 6 months post-DSLT treatment]
- Proportion of eyes needing medication stratified by number of IOP medications required [Time frame: 6 months post-DSLT treatment]
- Number and type of Secondary surgical interventions [Time frame: 6 months post-DSLT treatment]
Eligibility criteria
Inclusion criteria
- Adult patients scheduled to undergo DSLT treatment in one or both eyes.
- Diagnosis of ocular hypertension or primary open angle glaucoma (POAG).
- Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.
Exclusion criteria
- Previous glaucoma surgeries/interventions:
- Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
- Patients who have undergone cataract surgery within the prior 2 years.
- Secondary glaucoma:
- Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.
- Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- The Eye Institute of West Florida — Largo
Identifiers
NCT: NCT07390890 · ND-25-01